ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 573

Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis

Pascal Hilliquin1, Thomas Barnetche2, Guy Baudens3, Ralph Niarra4, Isabelle Idier5 and Alain Saraux6, 1Rheumatology, Hôpital Sud Francilien, Corbeil-Essonne, France, 2Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, 3Rheumatology, CHR Valenciennes, Valenciennes, France, 4Biostatistics, Keyrus of behalf of Roche SAS, Boulogne-Billancourt, France, 5Medical department, Chugai Pharma France, Paris La Defense, France, 6Rheumatology, CHU Brest, Brest, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biologic agents, rheumatoid arthritis (RA) and tocilizumab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: In France, tocilizumab (TCZ) subcutaneous (sc) 1st prescription and yearly renewal are restricted to hospital. Monitoring may be done by both office-based or hospital rheumatologists. The objective is to describe 12-month drug retention rate, efficacy and tolerance of TCZ sc in real life in rheumatoid arthritis (RA) patients (pts).

 

Methods: Prospective, multicentre, observational 18-month study including pts with moderate/severe active RA requiring TCZ sc as prescribed in real life. Primary endpoint: drug retention rate of TCZ sc at 12 months in pts followed by hospital- and office-based rheumatologists. Secondary endpoints: pts characteristics, concomitant treatments, adherence using the Compliance Questionnaire for Rheumatology (CQR5), efficacy and safety of TCZ sc. Statistical analysis: pts with ≥1 TCZ injection were analyzed for safety. Pts fulfilling inclusion and non-inclusion criteria were analyzed for efficacy.

 

Results: 291 pts were recruited, 288 were analysed for safety and 281 for efficacy. At baseline: mean age 56.2±12.5 years, females: 74.4%, at least 1 co-morbidity: 71%, mean RA duration 9.5±9.0 years, RF/ACPA +: 83.5%, erosive RA: 61.2%, mean DAS28ESR 4.76±1.22. Past RA treatments included DMARDs in 94.3%, mainly MTX (90.4%), and biologics in 63.3%. TCZ Mono (i.e. without csDMARD) was initiated in 42% and TCZ Combo in 57% of the pts, 84.9% of the latest received MTX (mean dose 17.2±4.4 mg/w). 151 pts completed M12, 26 pts had no M12 visit collected yet. 104 (37.1%) pts withdrew:  AE 19.4%, lack of efficacy 11.1%.  

At M12, drug retention rate was 63.3% in all pts, 61.8% in Mono, 64.1% in Combo (Fig.1). 2 Mono pts had an ongoing csDMARD, 6 Combo pts had no csDMARD. Total number of TCZ injections was 33.3±23.3 done by pt himself in 53.9%, at home in 92.7%. Adherence to TCZ sc was high in 85.4% of the 82 pts who fulfilled the CQR5. 47.3% used prednisone at 13.1±12.8 mg/day in the Mono and 8.4±4.7 in the Combo group.

At M12, 89% of the pts were followed at hospital, 11% by mixed or office-based rheumatologists. Mean DAS28ESR in all, Mono and Combo were 1.89±1.08, 1.67±1.03, 2.05±1.11 respectively. DAS28 remission and LDA were respectively 71.8% in all, 77.1% in Mono, 67.2% in Combo and 16.4% in all, 14.6% in Mono, 18.0% in Combo. No new safety signal was reported. 218 (75.7%) pts had at least one adverse event (AE), 41 (14.2%) had at least one serious AE including 7 serious infections.

 

Conclusion: In this 12-month interim analysis, drug retention rate was 63.3% in patients receiving TCZ sc in real life, with no difference between Mono and Combo groups. DAS28 remission/LDA was 88.2% in all patients, 91.7% in Mono and 85.2% in Combo. No new safety signal occurred. Final analysis will include remaining missing data.

 

 

Fig. 1. Kaplan-Meier curve of the drug retention rate in Mono and Combo groups – Efficacy population

 


Disclosure: P. Hilliquin, Roche SAS, 5,Chugai Pharma France, 5; T. Barnetche, Roche SAS, 5,Chugai Pharma France, 5; G. Baudens, Roche SAS, 5,Chugai Pharma France, 5; R. Niarra, Roche SAS, 3; I. Idier, Chugai Pharma France, 3; A. Saraux, Roche SAS, 5,Chugai Pharma France, 5.

To cite this abstract in AMA style:

Hilliquin P, Barnetche T, Baudens G, Niarra R, Idier I, Saraux A. Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/subcutaneous-tocilizumab-in-monotherapy-or-in-combination-with-dmard-in-patients-with-moderate-to-severe-active-rheumatoid-arthritis-observational-study-to-describe-real-world-drug-retention-rat/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/subcutaneous-tocilizumab-in-monotherapy-or-in-combination-with-dmard-in-patients-with-moderate-to-severe-active-rheumatoid-arthritis-observational-study-to-describe-real-world-drug-retention-rat/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology